MX2017016258A - Antigenos de leucemia mieloide aguda (aml) y usos de los mismos. - Google Patents

Antigenos de leucemia mieloide aguda (aml) y usos de los mismos.

Info

Publication number
MX2017016258A
MX2017016258A MX2017016258A MX2017016258A MX2017016258A MX 2017016258 A MX2017016258 A MX 2017016258A MX 2017016258 A MX2017016258 A MX 2017016258A MX 2017016258 A MX2017016258 A MX 2017016258A MX 2017016258 A MX2017016258 A MX 2017016258A
Authority
MX
Mexico
Prior art keywords
aml
antigens
aml antigens
antigen
present
Prior art date
Application number
MX2017016258A
Other languages
English (en)
Inventor
Aletta Gillissen Marijn
Deborah Hazenberg Mette
Spits Hergen
Kedde Martijn
Maria Wilhelmina Van Helden Paula
POS Wouter
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of MX2017016258A publication Critical patent/MX2017016258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Veterinary Medicine (AREA)

Abstract

La presente i nvención proporciona compuestos novedosos que comprenden un antígeno de células de AML y usos de los mismos.
MX2017016258A 2015-06-24 2016-06-24 Antigenos de leucemia mieloide aguda (aml) y usos de los mismos. MX2017016258A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173662 2015-06-24
EP16150621 2016-01-08
PCT/NL2016/050449 WO2016209079A1 (en) 2015-06-24 2016-06-24 Aml antigens and uses thereof

Publications (1)

Publication Number Publication Date
MX2017016258A true MX2017016258A (es) 2018-04-20

Family

ID=56567655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016258A MX2017016258A (es) 2015-06-24 2016-06-24 Antigenos de leucemia mieloide aguda (aml) y usos de los mismos.

Country Status (14)

Country Link
US (2) US11524989B2 (es)
EP (1) EP3313870B1 (es)
JP (2) JP7010704B2 (es)
KR (1) KR20180118101A (es)
CN (1) CN107810191B (es)
AU (2) AU2016281424B2 (es)
BR (1) BR112017027677A2 (es)
CA (1) CA2989551A1 (es)
DK (1) DK3313870T3 (es)
EA (1) EA201792492A1 (es)
HK (1) HK1247934A1 (es)
MX (1) MX2017016258A (es)
TW (1) TWI751110B (es)
WO (1) WO2016209079A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2461246T3 (es) 2005-05-11 2014-05-19 Dinona Inc. El epítopo de CD43 específico de la leucemia aguda y del linfoma linfoblástico y sus usos
KR100738401B1 (ko) * 2005-05-11 2007-07-11 다이노나(주) 급성백혈병- 및 림프모구 림프종 특이 ｃｄ43의항원결정부위 및 이의 용도
US7622560B2 (en) 2005-05-11 2009-11-24 Dinona Inc. Monoclonal antibody specific for CD43 epitope
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
FI1974017T4 (fi) 2005-12-09 2023-09-14 Välineitä ja menetelmiä, joilla voidaan vaikuttaa vasta-ainetta tuottavien solujen stabiliteettiin
CN103709252B (zh) 2006-06-07 2016-12-07 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
DK2245063T3 (en) * 2007-12-18 2015-12-07 Bioalliance Cv Antibodies that recognize carbohydrate AN EPITOPE ON CD-43 AND CEA expressed CANCER CELLS AND PRACTICES BY WHICH THEY USED
US9718874B2 (en) 2011-12-02 2017-08-01 Aimm Therapeutics B.V. Influenza A virus specific antibodies
KR20240042192A (ko) * 2013-12-17 2024-04-01 크링 바이오테라퓨틱스 비.브이. 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법

Also Published As

Publication number Publication date
CN107810191B (zh) 2023-06-13
WO2016209079A1 (en) 2016-12-29
AU2020294288B2 (en) 2022-05-05
JP7010704B2 (ja) 2022-02-10
US20230235018A1 (en) 2023-07-27
NZ738289A (en) 2021-08-27
JP2022000038A (ja) 2022-01-04
DK3313870T3 (da) 2020-08-31
TW201718631A (zh) 2017-06-01
AU2020294288A1 (en) 2021-01-28
BR112017027677A2 (pt) 2018-08-28
TWI751110B (zh) 2022-01-01
EA201792492A1 (ru) 2018-07-31
KR20180118101A (ko) 2018-10-30
US20180170998A1 (en) 2018-06-21
JP2018520670A (ja) 2018-08-02
CN107810191A (zh) 2018-03-16
AU2016281424A1 (en) 2018-01-04
EP3313870A1 (en) 2018-05-02
CA2989551A1 (en) 2016-12-29
HK1247934A1 (zh) 2018-10-05
AU2020294288B9 (en) 2022-05-19
EP3313870B1 (en) 2020-06-03
AU2016281424B2 (en) 2020-12-24
US11524989B2 (en) 2022-12-13

Similar Documents

Publication Publication Date Title
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
MX2019007021A (es) Anticuerpos il-11ra.
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501763A1 (en) Multispecific antibodies
MX2019007020A (es) Anticuerpos il-11.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY191581A (en) Anti-pd-1 antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MY193661A (en) Anti-tim3 antibodies and methods of use
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
MX2017016258A (es) Antigenos de leucemia mieloide aguda (aml) y usos de los mismos.
MX2015010789A (es) Anticuerpos anti-pcsm.
NZ744340A (en) Anti-jagged1 antibodies and methods of use